Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132618) titled 'Efficacy and Safety of First-Line Therapy with Gemox Chemotherapy Combined with Lenvatinib and Iparomlimab and Tuvonralimab in Patients with Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma' on Sept. 16.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital, Sichuan University
Condition:
Intrahepatic cholangiocarcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-16
Target Sample Size: treatment group:43;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?pr...